Betta Pharmaceuticals Co (SZSE:300558) Total Current Assets : ¥1,292 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Betta Pharmaceuticals Co's total current assets for the quarter that ended in Mar. 2024 was ¥1,292 Mil.

Betta Pharmaceuticals Co Total Current Assets Historical Data

The historical data trend for Betta Pharmaceuticals Co's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Betta Pharmaceuticals Co Total Current Assets Chart

Betta Pharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

792.24

1,847.81

1,653.94

1,732.84

1,525.88

Betta Pharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															1,491.36	1,723.64	1,750.13	1,525.88	1,291.52

Betta Pharmaceuticals Co Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Betta Pharmaceuticals Co's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	752.536	+	289.02	+	327.502	+	156.823
	=	1,526

Betta Pharmaceuticals Co's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	554.561	+	210.976	+	336.995	+	188.99
	=	1,292

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Betta Pharmaceuticals Co (SZSE:300558) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Betta Pharmaceuticals Co's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	554.561	-	3713.62	+	0.75 * 207.417	+	0.5 * 336.995
=	-2,835

Betta Pharmaceuticals Co Total Current Assets Related Terms

Thank you for viewing the detailed overview of Betta Pharmaceuticals Co's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Betta Pharmaceuticals Co (SZSE:300558) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » Total Current Assets

Traded in Other Exchanges

N/A

Address

No.355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Zhejiang Province, Hangzhou, CHN

Website

http://www.bettapharma.com

Betta Pharmaceuticals Co Ltd is a hi-tech pharmaceutical enterprise focuses on research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates through China.

Executives

Wang Jia Bing	Directors, executives
Ding Lie Ming	Directors, executives
Cai Wan Yu	Executives

Betta Pharmaceuticals Co (SZSE:300558) Headlines

No Headlines